TNF-alpha Inhibitors and Neutropenia: Current State of Art
Author(s) -
Emmanuel Andrès,
Noel Lorenzo Villalba,
Abrar-Ahmad Zulfiqar,
Yasmine Maouche,
Khalid Serraj,
Jacques-Eric Gottenberg
Publication year - 2020
Publication title -
journal of cellular immunology
Language(s) - English
Resource type - Journals
ISSN - 2689-2812
DOI - 10.33696/immunology.2.034
Subject(s) - adalimumab , golimumab , etanercept , infliximab , medicine , neutropenia , tumor necrosis factor alpha , certolizumab pegol , immunology , intensive care medicine , chemotherapy
Drug-induced severe neutropenia, defined as an absolute neutrophil count (NC) ≤ 0.5 x 109/L or a complete lack of neutrophils in circulating blood, is a potentially severe complication that has been related to most classes of drugs [1]. For the majority of drugs, the risk is likely to be very small. For medications such as antithyroid drugs, ticlopidine, clozapine, cotrimoxazole (trimethoprimsulfamethoxazole), sulfasalazine, methimazole, and dipyrone, the risk may be higher [2,3]. Although the pathogenesis is not yet fully clear, direct toxicity to the myeloid cell line and immune-mediated destruction are the main reported mechanisms [4].
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom